A randomized, double-blind, placebo-controlled, single and multiple-dose-escalation, phase 1 study in healthy volunteers and patients with ulcerative colitis to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GRT-001 (MONOlith trial)
GRT-1C101
Phase 1 other active
Quick answer
A randomized, double-blind, placebo-controlled, single and multiple-dose-escalation, phase 1 study in healthy volunteers and patients with ulcerative colitis to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GRT-001 (MONOlith trial) for Ulcerative colitis is a Phase 1 program (other) at Rani Therapeutics Holdings with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Rani Therapeutics Holdings
- Indication
- Ulcerative colitis
- Phase
- Phase 1
- Modality
- other
- Status
- active